Dongkook Pharmaceutical Co 086450.KQ · KRW

Its shares trade on KOSDAQ under the ticker 086450.KQ. It has been listed since 29 May 2007. In the fiscal year to 31 December 2025, it reported revenue of ₩926.88bn and net income of ₩66.02bn. At that date it held total assets of ₩1.06trn and shareholders' equity of ₩663.74bn.

DongKook Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceuticals. The company is headquartered in Seoul, Seoul. The company went IPO on 2007-05-29. The firm develops and provides remedies for oral troubles, skin troubles and gynecology diseases, contrast mediums, anesthetics, anticancer medicines and circulatory system agents. The company also provides other pharmaceuticals, such as remedies for arthritis and pancreatitis, antiphlogistic, anodynes, antibiotics and vitamins, as well as raw materials for pharmaceuticals. In addition, it is engaged in the rental business. The firm distributes its products within domestic market and to overseas markets, such as Japan, Germany, India, Brazil and Mexico, among others.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Gi Beom GwonChairman, since 2022
• Mr. Jun Ho SongCo-President, Chief Executive Officer, Director, since 2012
• Mr. Se Yil JeonCo-President, Director
• Mr. Jong Jin LeeCo-President, Director
• Mr. Heung Ju OhVice Chairman, since 2022
• Mr. Sun Gang HongVice President
• Mr. Gyeong Ju HwangVice President
• Mr. Gwang Jong KimVice President
• Mr. Geun Yeong LeeVice President, since 2022
• Hui Jae ParkVice President
• Mun Hwan JungManaging Director
• Mr. Jae Wuk LeeManaging Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.